Utility of PharmacoGenomics for Reducing Adverse Drug Effects

Inclusion Criteria: * Subject plans to undergo current index PGx testing at the time of enrollment or underwent current index PGx testing within the prior 1-year period, for genes known to influence metabolism of at least one target drug * Subject is aged ≥18 years * Subject is able and willing to provide written informed consent * Subject reveals a history of at least one TDAE or an inadequate therapeutic effect from a target drug over the 12-month period preceding expected receipt of PGx test results * Subject is not taking an investigational medication or in an interventional trial that would interfere with participation in the registry Exclusion Criteria: * Subject is currently hospitalized * Subject's medical and medication history is unavailable over the 90-day periods preceding and following the receipt of pharmacogenomic test results * Subject is unable to provide an accurate history due to mental incapacity * Subject is known to have undergone prior pharmacogenomic testing (exclusive of the current index PGx testing) for genes specific to the target drugs within the 2-year period preceding enrollment and these results have been previously evaluated